<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NALBUPHINE HYDROCHLORIDE</span><br/>(nal'byoo-feen)<br/><span class="topboxtradename">Nubain<br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">analgesic</span>; <span class="classification">narcotic (opiate) agonist-antagonist</span><br/><b>Prototype: </b>Pentazocine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>10 mg/mL, 20 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Synthetic narcotic analgesic with agonist and weak antagonist properties. Analgesic potency is about 3 or 4 times greater
         than that of pentazocine and approximately equal to that produced by equivalent doses of morphine. On a weight basis, produces
         respiratory depression about equal to that of morphine; however, in contrast to morphine, doses &gt;30 mg produce no further
         respiratory depression. Antagonistic potency is approximately one fourth that of naloxone and about 10 times greater than
         that of pentazocine.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Analgesic action that relieves moderate to severe pain with apparently low potential for dependence.</p>
<h1><a name="uses">Uses</a></h1>
<p>Symptomatic relief of moderate to severe pain. Also preoperative sedation analgesia and as a supplement to surgical anesthesia.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>History of hypersensitivity to drug. Safety during pregnancy (category C) or lactation is not established. Prolonged use during
         pregnancy could result in neonatal withdrawal.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of emotional instability or drug abuse; head injury, increased intracranial pressure; impaired respirations; impaired
         kidney or liver function; MI; biliary tract surgery.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Moderate to Severe Pain</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV/IM/SC</span> 1020 mg q36h prn (max: 160 mg/d)<br/><span class="rdage">Child:</span> <span class="rdroute">IV/IM/SC</span> 0.10.15 mg/kg q36h prn<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Intramuscular/</span><span class="adminroutetype">Subcutaneous</span><br/><ul>
<li>Inject undiluted.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>
                     					Note: Verify correct rate of IV injection in infants, children with physician.
                     				
                  </li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Give undiluted.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give at a rate of 10 mg or fraction thereof over 35 min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<b>Diazepam,</b>
<b>pentobarbital,</b>
<b>promethazine,</b>
<b>thiethylperazine.</b>
<span class="incompattype">Y-site:</span>
<b>Nafcillin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store at 15°30°C (59°86°F), avoid freezing.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Hypertension, hypotension, bradycardia, tachycardia, flushing. <span class="typehead">GI:</span> Abdominal cramps, bitter taste, <span class="speceff-common">nausea, vomiting,</span> dry mouth. <span class="typehead">CNS:</span>
<span class="speceff-common">Sedation, dizziness,</span> nervousness, depression, restlessness, crying, euphoria, dysphoria, distortion of body image, unusual dreams, confusion,
      hallucinations; numbness and tingling sensations, headache, vertigo. <span class="typehead">Respiratory:</span> Dyspnea, asthma, <span class="speceff-life">respiratory depression</span>. <span class="typehead">Skin:</span> Pruritus, urticaria, burning sensation, <span class="speceff-common">sweaty, clammy skin</span>. <span class="typehead">Special Senses:</span> Miosis, blurred vision, speech difficulty. <span class="typehead">Urogenital:</span> Urinary urgency. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol</b> and other <span class="classification">cns depressants</span> add to CNS depression. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Onset:</span>  23 min IV; 15 min IM. <span class="typehead">Peak:</span> 30 min IV. <span class="typehead">Duration:</span> 36 h. <span class="typehead">Distribution:</span> Crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead"> Elimination:</span> Eliminated in urine. <span class="typehead">Half-Life:</span> 5 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess respiratory rate before drug administration. Withhold drug and notify physician if respiratory rate falls below 12.</li>
<li>Watch for allergic response in persons with sulfite sensitivity.</li>
<li>Administer with caution to patients with hepatic or renal impairment.</li>
<li>Monitor ambulatory patients; nalbuphine may produce drowsiness.</li>
<li>Watch for respiratory depression of newborn if drug is used during labor and delivery.</li>
<li>Avoid abrupt termination of nalbuphine following prolonged use, which may result in symptoms similar to narcotic withdrawal:
            nausea, vomiting, abdominal cramps, lacrimation, nasal congestion, piloerection, fever, restlessness, anxiety.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not drive or engage in potentially hazardous activities until response to drug is known.</li>
<li>Avoid alcohol and other CNS depressants.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>